Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in HZD?
Horizon Discovery Group PLC: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Market applauds Horizon Discovery's Dharmacon buy

Enlarged company can become an emerging leader in the application of gene modulation technologies
picture of drug researcher
INVESTMENT OVERVIEW: HZD The Big Picture
Demand for both companies' products is rising rapidly

A company that sees its share price surge after a huge share placing and acquisition can fairly confidently assume the market likes the deal.

And that’s where Horizon Discovery PLC (LON:HZD) finds itself after its shares jumped 12% on the back of the purchase of General Electric subsidiary Dharmacon.

It’s not hard to see why the market gave such as positive response.

Revenues to double

At a stroke, Horizon has more than doubled its revenues but more importantly given itself a way in to the hugely important academic section of the drug development market.

Horizon, combined with Dharmacon, can become an emerging leader in the application of gene modulation technologies in life science research, according to Horizon chief executive Darrin Disley.

“Brand recognition, and sales, marketing (including eCommerce) and the distribution channel would transform the opportunity for Horizon's product portfolio."

The purchase cost is US$85mln in cash and shares with a £80mln placing at 205p to fund it.

Backing has come from major institutional shareholders Woodford and Perpetual, which between them will own a 31.5% stake following the transaction. General Electric will own 8.8% of Horizon

Horizon's benefits from Dharmacon acquisition

- Expansion of the product portfolio to gene modulation and gene expression technologies,

- Accessing a global academic/government research customer base where Horizon historically has had little brand awarenes

- Increasing the scalability and global reach of the business by delivering a high proportion of product sales through Dharmacon's eCommerce platfor

- Revenue and cost synergies, with the enlarged group’s cost to be reduced by 10-15% within 18 months and sales to grow again at Dharmacon

Gene editing

Horizon specialises in gene-editing, namely altering the biological codes that tell a cell how to behave.

It designs and engineers genetically-modified cells that replicate certain mutations for use in applied research and clinical applications.

The vast majority of its offering is based around accurately reproducing the mutations and anomalies found in cells that can cause diseases like cancer.

Horizon boasts a catalogue of over 23,000 cell generation and application services. It allows researchers to better understand the genetic drivers of the disease in order to develop therapies to treat it.

Ten of the best selling drugs last year were biologic therapeutics, but access to bioproduction cell lines for their manufacture can be cost prohibitive, which is where Horizon comes in.

Further modification of cells

Underlying its growing market presence, towards the end of 2016 the group licensed its cell line production technology to the Centre for Process Innovation (CPI) and the National Institute for Bioprocessing Research (NIBRT) and Training.

The collaborations mean any organisation that goes through CPI or NIBRT will be able to access Horizon's biomanufacturing cell lines for research purposes.

Terms of the licences will allow for further modification of cells accessed through the CPI or NIBRT and establishes a potential long-term revenue stream for Horizon.

The group’s commercial offering has already been adopted by around 1,400 research organisations across 50 countries.

Sales at the double

Sales in 2016 were £24.1mln (£20.2mln), but 2017 should see these rise to at least £30-35mln, Horizon confirm with the Dharmacon deal.

Product revenues rose by 45% to £11.3mln with immuno-oncology sales rising 40% to £1.5mln as 10 developments now use its platform.

Gross margins rose to 54%, from 49%, reflecting the growing importance of the products division said Horizon and underlying losses [EBITDA] reduced to £3.8mln (FY15: £4.6mln). There was a pre-tax loss of £12.5mln (£10.5mln).

 

View full HZD profile View Profile

Horizon Discovery Group PLC Timeline

Related Articles

consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use